Zhixiong Ye

USPTO Granted Patents = 21 (Patent Applications = 3)

CIPO Patents = 2

EPO Patents = 3 (Patent Applications = 2)

Average Co-Inventor Count = 5.6

ph-index = 7

Forward Citations = 216(Granted Patents)

Location History:

Lawrenceville, NJ (US) (2001 - 2002)
Princeton, NJ (US) (2002 - 2008)
West Windsor, NJ (US) (2010 - 2017)
Beijing, CN (2015 - 2022)

Company Filing History:

Agios Pharmaceuticals, Inc.

patents

1 out of 21

Servier Pharmaceuticals LLC

patents

4. 1 out of 2,405

Merck Sharp + Dohme Corp.

patents

Years Active: 2001-2022

Loading Chart...

21 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 11325914 - Inhibitors of cellular metabolic processes (2022-05-10),

2. 10800782 - Inhibitors of cellular metabolic processes (2020-10-13),

3. 10329298 - Inhibitors of cellular metabolic processes (2019-06-25),

4. 10000479 - Compounds and their methods of use (2018-06-19),

5. 9856279 - Therapeutically active compositions and their methods of use (2018-01-02),

6. 9662327 - Phenyl and pyridinyl substituted piperidines and piperazines as inhibitors of IDH1 mutants and their use in treating cancer (2017-05-30),

7. 9365545 - Therapeutic compounds and compositions (2016-06-14),

8. 9108921 - Therapeutic compounds and compositions (2015-08-18),

9. 7652024 - Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators (2010-01-26),

10. 7414057 - Piperazine urea derivatives as melanocortin-4 receptor agonists (2008-08-19),

11. 7329673 - Acylated spiropiperidine derivatives as melanocortin-4 receptor agonists (2008-02-12),

12. 7276520 - Bicyclic piperidine derivatives as melanocortin-4 receptor agonists (2007-10-02),

13. 7160886 - Acylated piperazine derivatives as melanocortin-4 receptor agonists (2007-01-09),

14. 7115628 - Bridged piperidine derivatives as melanocortin receptor agonists (2006-10-03),

15. 7015235 - Acylated piperidine derivatives as melanocortin-4 receptor agonists (2006-03-21),

Title: Innovations of Zhixiong Ye in Cellular Metabolism

Introduction: Zhixiong Ye is a notable inventor based in Princeton, NJ, known for his significant contributions to the field of pharmaceuticals. With an impressive portfolio of 21 patents, he focuses primarily on developing therapeutic agents to treat malignancies by targeting cellular metabolic processes.

Latest Patents: Among his latest innovations, Zhixiong Ye has disclosed MAT2A inhibitor compounds. These compounds are designed as therapeutic agents that are effective in combating various types of cancers. The disclosed compounds conform to a general formula (IA), where the elements R, R, R, R, and R are specifically defined. This research reflects his commitment to improving treatment options through innovative biochemistry.

Career Highlights: Zhixiong Ye has built a distinguished career in the biopharmaceutical sector. He has notably worked with reputable companies such as Merck & Company, Inc. and Agios Pharmaceuticals, Inc. His roles have contributed significantly to the advancement of therapeutic methodologies targeting metabolic pathways in cancer therapies.

Collaborations: Throughout his career, Zhixiong Ye has collaborated with several esteemed colleagues, including Ravi P Nargund and Raman Kumar Bakshi. These collaborations have not only enriched his research but also facilitated the development of groundbreaking therapies.

Conclusion: Zhixiong Ye's innovative work in the field of metabolic processes offers promising avenues for the treatment of malignancies. His extensive list of patents illustrates his dedication to advancing medical technology and improving patient outcomes. As research continues to evolve, the impact of his contributions will likely resonate within the scientific community and beyond.

This text is generated by artificial intelligence and may not be accurate.